Posted by Michael Wonder on 06 Sep 2022
Swissmedic authorizes Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older
5 September 2022 - Novavax, today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17 and as a heterologous and homologous booster dose for adults aged 18 and older.
The authorisation for adolescents aged 12 through 17 is based on data from the on-going paediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S. to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid.
